| Li, Linfa |
NCT06750419: 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study |
|
|
| Recruiting | 3 | 82 | RoW | 89Zr-TLX250 PET/CT, 89Zr-DFO-girentuximab, 89Zr-girentuximab, 89Zr-DFO-TFP-GTX, 89Zirconium-labelled girentuximab | Telix Pharmaceuticals (Innovations) Pty Limited | Clear Cell Renal Cell Carcinoma | 06/26 | 06/26 | | |
| Yu, Xinmin |
FGCL-4592-898, NCT05301517: A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies |
|
|
| Completed | 3 | 159 | RoW | SEPO®, Recombinant human erythropoietin-α [rHuEPO-α], Roxadustat, FG-4592 | FibroGen | Chemotherapy Induced Anemia | 04/23 | 04/23 | | |
NCT06616532: PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 404 | RoW | PM8002, Paclitaxel, Topotecan | Biotheus Inc. | SCLC | 01/27 | 12/28 | | |
| Active, not recruiting | 3 | 600 | Europe, Canada, US, RoW | Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere | OncoC4, Inc., BioNTech SE | Non Small Cell Lung Cancer | 06/26 | 06/27 | | |
NCT04691388: A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor |
|
|
| Completed | 2 | 29 | RoW | sintilimab combined with anlotinib | Zhejiang Cancer Hospital, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Innovent Biologics (Suzhou) Co. Ltd. | NSCLC | 09/24 | 12/24 | | |
NCT04398940: A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 71 | RoW | TQ-B3139 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 01/22 | 10/22 | | |
NCT05322499: Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer |
|
|
| Not yet recruiting | 2 | 80 | RoW | Camrelizumab, SHR-1210, Irinotecan, Paclitaxel, Paclitaxel-albumin, Docetaxel, Anlotinib | Zhejiang Cancer Hospital | Stage IV Esophagus Squamous Cell Carcinoma | 04/23 | 04/25 | | |
NCT06235983: A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors |
|
|
| Active, not recruiting | 1 | 12 | RoW | LY3537982, Olomorasib | Eli Lilly and Company | Advanced Solid Tumors | 04/26 | 04/27 | | |
NCT05369312: Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients |
|
|
| Not yet recruiting | 1 | 230 | RoW | BPI-442096 | Betta Pharmaceuticals Co., Ltd. | Solid Tumor, Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer | 05/24 | 05/25 | | |
| YANG, HONGJIAN |
CLOVER, NCT03926091: Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer |
|
|
| Recruiting | 3 | 2172 | RoW | Docetaxel, docetaxel injection, Cyclophosphamide, Cyclophosphamide injection | Fudan University | Breast Cancer | 11/24 | 11/25 | | |
NCT02062489: Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients |
|
|
| Recruiting | 3 | 688 | RoW | Tamoxifen, Nolvadex, Placebo | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Breast Cancer | 05/25 | 05/26 | | |
NCT03351062: Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer |
|
|
| Recruiting | 3 | 844 | RoW | Tamoxifen, Tamoxifen citrate, Toremifene, fareston | Chinese Anti-Cancer Association, Fudan University, Henan Cancer Hospital, The First Hospital of Jilin University, Southwest Hospital, China, First Hospital of China Medical University, Guangdong Provincial People's Hospital, Harbin Medical University, First Affiliated Hospital of Chongqing Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Jiangsu Provincial People's Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Zhejiang Cancer Hospital, Tianjin Medical University Cancer Institute and Hospital, Union hospital of Fujian Medical University, Hebei Tumor Hospital, Hunan Cancer Hospital, Affiliated Hospital of Qinghai University, Wuhan TongJi Hospital, Hainan People's Hospital, The Third Affiliated Hospital of Kunming Medical College., The Third Affiliated Hospital of Nanchang University | Breast Cancer Female | 12/25 | 12/25 | | |
NCT05103293: PTC Guiding Neoadjuvant Treatment in Breast Cancer |
|
|
| Completed | 2 | 86 | RoW | patient-derived tumor-like cell clusters drug sensitivity test, PTC | Zhejiang Cancer Hospital | Pathological Conditions, Signs and Symptoms | 12/23 | 12/23 | | |
PLEDGE, NCT05120180: Effect of ALND With Vein Branches Reservation on Postoperative Upper Limb Edema and Dysfunction in Breast Cancer |
|
|
| Active, not recruiting | N/A | 258 | RoW | axillary lymph node dissection with vein branches reservation, axillary lymph node dissection without vein branches reservation | Xiangyun Zong | Breast Cancer Lymphedema | 04/24 | 04/29 | | |
PLEDGE-R, NCT05246592: Effect of the Axillary Lymphatic /Vein Reflux Ratio on Postoperative Upper Limb Edema and Dysfunction in Breast Cancer |
|
|
| Active, not recruiting | N/A | 258 | RoW | Branches Sparing, None Branches Sparing | Xiangyun Zong | Breast Cancer Lymphedema | 04/24 | 04/29 | | |
| Shang, Jinbiao |
| Active, not recruiting | 3 | 291 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib | Loxo Oncology, Inc., Eli Lilly and Company | Medullary Thyroid Cancer | 05/23 | 02/26 | | |
NCT06429514: Study on the Mechanism of Ganoderma Lucidum Spore Powder in the Treatment of Depression |
|
|
| Completed | N/A | 298 | RoW | Ganoderma lucidum spore powder, placebo | Ling Zhiqiang, Zhejiang Shouxiangu Pharmaceutical Co,. Ltd. | Depression, Thyroid Cancer | 05/24 | 05/24 | | |
